Routine exercise ameliorates the metabolic side-effects of treatment with the atypical antipsychotic drug olanzapine in rats

International Journal of Neuropsychopharmacology

Volumn 17, Issue 1, 2014, Pages 77-90

  Boyda, H N ^a   Ramos Miguel, A ^a,b   Procyshyn, R M ^a,b   Topfer E ^a   Lant, N ^a   Choy, H H T ^a   Wong, R ^a   Li, L ^a   Pang, C C Y ^a   Honer, W G ^a,b   Barr, A M ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b British Columbia Mental Health and Addictions Research Institute   (Canada)

Author keywords

Antipsychotic; exercise; glucose tolerance; GLUT4; insulin resistance; olanzapine

Indexed keywords

GLUCOSE TRANSPORTER 4; OLANZAPINE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; SLC2A4 PROTEIN, RAT;

ABDOMINAL FAT; AEROBIC EXERCISE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; EXERCISE INTENSITY; FEMALE; FOOD INTAKE; GLUCOSE INTOLERANCE; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; INSULIN RESISTANCE; NONHUMAN; PRIORITY JOURNAL; RAT; SKELETAL MUSCLE; WEIGHT GAIN; ANIMAL; BLOOD; DRUG EFFECTS; GLUCOSE TOLERANCE TEST; METABOLISM; MOTOR ACTIVITY; PHYSIOLOGY;

ABDOMINAL FAT; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORTER TYPE 4; MOTOR ACTIVITY; MUSCLE, SKELETAL; RATS;

EID: 84888628535     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145713000795     Document Type: Article

References (68)

1. Adeneye AA, Agbaje EO, Olagunju JA (2011) Metformin: an effective attenuator of risperidone-induced insulin resistance hyperglycemia and dyslipidemia in rats. Indian J Exp Biol 49:332-338.
2. Albaugh VL, Henry CR, Bello NT, Hajnal A, Lynch SL, Halle B, Lynch CJ (2006) Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity (Silver Spring) 14:36-51. (Pubitemid 46214773)
3. Albaugh VL, Singareddy R, Mauger D, Lynch CJ (2011) A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers. PLoS ONE 6:e22662. doi: 10.1371/journal. pone.0022662.
4. Araya AV, Orellana X, Godoy D, Soto L, Fiedler J (2013) Effect of exercise on circulating levels of brain-derived neurotrophic factor (BDNF) in overweight and obese subjects. Horm Metab Res 45(7):541-544.
5. Baptista T, El Fakih Y, Uzcategui E, Sandia I, Talamo E, Araujo de Baptista E, Beaulieu S (2008) Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs 22:477-495. (Pubitemid 351693690)
6. Baptista T, Rangel N, El Fakih Y, Uzcategui E, Galeazzi T, Beaulieu S, Araujo de Baptista E (2009) Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial. Pharmacopsychiatry 42:14-19.
7. Baptista T, Araujo de Baptista E, Ying Kin NM, Beaulieu S, Walker D, Joober R, Lalonde J, Richard D (2002) Comparative effects of the antipsychotics sulpiride or risperidone in rats. I: bodyweight, food intake, body composition, hormones and glucose tolerance. Brain Res 957:144-151. (Pubitemid 35346582)
8. Boutcher SH (2011) High-intensity intermittent exercise and fat loss. J Obes 2011:868305.
9. Boyda HN, Tse L, Procyshyn RM, Honer WG, Barr AM (2010a) Preclinical models of antipsychotic drug-induced metabolic side effects. Trends Pharmacol Sci 31:484-497.
10. Boyda HN, Tse L, Procyshyn RM, Wong D, Wu TK, Pang CC, Barr AM (2010b) A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model. Prog Neuropsychopharmacol Biol Psychiatry 34:945-954.
11. Boyda HN, Procyshyn RM, Tse L, Wong D, Pang CC, Honer WG, Barr AM (2012a) Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats. Neuropharmacology 62:1391-1400.
12. Boyda HN, Procyshyn RM, Tse L, Hawkes E, Jin CH, Pang CC, Honer WG, Barr AM (2012b) Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats. J Psychiatry Neurosci 37:407-415.
13. Boyda HN, Procyshyn RM, Pang CC, Hawkes E, Wong D, Jin CH, Honer WG, Barr AM (2013a) Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine. PLoS ONE 8:e53459. doi: 10.1371/journal.pone.0053459.
14. Boyda HN, Procyshyn RM, Tse L, Xu J, Jin CH, Wong D, Pang CC, Honer WG, Barr AM (2013b) Antipsychotic polypharmacy increases metabolic dysregulation in female rats. Exp Clin Psychopharmacol 21(2):164-171.
15. Brandl EJ, Tiwari AK, Lett TA, Shaikh SA, Lieberman JA, Meltzer HY, Kennedy JL, Muller DJ (2013) Exploratory study on association of genetic variation in TBC1D1 with antipsychotic-induced weight gain. Hum Psychopharmacol 28(2):183-187.
16. Buckley PF, Correll CU (2008) Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry 69(Suppl. 1):4-17.
17. Chien IC, Hsu JH, Bih SH, Lin CH, Chou YJ, Lee CH, Chou P (2008) Prevalence, correlates, and disease patterns of antipsychotic use in Taiwan. Psychiatry Clin Neurosci 62:677-684.
18. Chintoh AF, Mann SW, Lam TK, Giacca A, Remington G (2008a) Insulin resistance following continuous, chronic olanzapine treatment: an animal model. Schizophr Res 104:23-30.
19. Chintoh AF, Mann SW, Lam L, Lam C, Cohn TA, Fletcher PJ, Nobrega JN, Giacca A, Remington G (2008b) Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. J Clin Psychopharmacol 28:494-499.
20. Chintoh AF, Mann SW, Lam L, Giacca A, Fletcher P, Nobrega J, Remington G (2009) Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model. Schizophr Res 108:127-133.
21. Coccurello R, Moles A (2010) Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacol Ther 127:210-251.
22. Cooper GD, Pickavance LC, Wilding JP, Halford JC, Goudie AJ (2005) A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology (Berl) 181:80-89. (Pubitemid 41440918)
23. Das C, Mendez G, Jagasia S, Labbate LA (2012) Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments. Ann Clin Psychiatry 24:225-239.
24. Davey KJ, O'Mahony SM, Schellekens H, O'Sullivan O, Bienenstock J, Cotter PD, Dinan TG, Cryan JF (2012) Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters. Psychopharmacology (Berl) 221:155-169.
25. Ehret M, Goethe J, Lanosa M, Coleman CI (2010) The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis. J Clin Psychiatry 71:1286-1292.
26. Fam BC, Rose LJ, Sgambellone R, Ruan Z, Proietto J, Andrikopoulos S (2012) Normal muscle glucose uptake in mice deficient in muscle GLUT4. J Endocrinol 214:313-327.
27. Fell MJ, Neill JC, Anjum N, Peltola LM, Marshall KM (2008) Investigation into the influence of a high fat diet on antipsychotic-induced weight gain in female rats. J Psychopharmacol 22:182-186. (Pubitemid 351322855)
28. Ferno J, Vik-Mo AO, Jassim G, Havik B, Berge K, Skrede S, Gudbrandsen OA, Waage J, Lunder N, Mork S, Berge RK, Jorgensen HA, Steen VM (2009) Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver. Psychopharmacology (Berl) 203:73-84.
29. Fiedorowicz JG, Miller DD, Bishop JR, Calarge CA, Ellingrod VL, Haynes WG (2012) Systematic review and meta-analysis of pharmacological interventions for weight gain from antipsychotics and mood stabilizers. Curr Psychiatry Rev 8:25-36.
30. Hamdy O, Porramatikul S, Al-Ozairi E (2006) Metabolic obesity: the paradox between visceral and subcutaneous fat. Curr Diabetes Rev 2:367-373. (Pubitemid 44734225)
31. Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H (2007) Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 32:289-297. (Pubitemid 46106936)
32. Hussey SE, McGee SL, Garnham A, McConell GK, Hargreaves M (2012) Exercise increases skeletal muscle GLUT4 gene expression in patients with type 2 diabetes. Diabetes Obes Metab 14:768-771.
33. Jassim G, Skrede S, Vazquez MJ, Wergedal H, Vik-Mo AO, Lunder N, Dieguez C, Vidal-Puig A, Berge RK, Lopez M, Steen VM, Ferno J (2011) Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat. Psychopharmacology (Berl) 219(3):783-794.
34. Kuo FC, Lee CH, Hsieh CH, Kuo P, Chen YC, Hung YJ (2012) Lifestyle modification and behavior therapy effectively reduce body weight and increase serum level of brain-derived neurotrophic factor in obese non-diabetic patients with schizophrenia. Psychiatry Res. doi: 10.1016/j.psychres.2012.11.020.
35. Leung JY, Barr AM, Procyshyn RM, Honer WG, Pang CC (2012) Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system. Pharmacol Ther 135:113-122.
36. Loke YK, Kwok CS, Singh S (2011) Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ 342:d1309.
37. Mann S, Chintoh A, Giacca A, Fletcher P, Nobrega J, Hahn M, Remington G (2012) Chronic olanzapine administration in rats: effect of route of administration on weight, food intake and body composition. Pharmacol Biochem Behav 103:717-722.
38. Manu P, Correll CU, van Winkel R, Wampers M, De Hert M (2012) Prediabetes in patients treated with antipsychotic drugs. J Clin Psychiatry 73:460-466.
39. Martins PJ, Haas M, Obici S (2011) Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance. Diabetes 59:2418-2425.
40. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80:19-32. (Pubitemid 41587460)
41. McIntyre RS, Jerrell JM (2008) Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Arch Pediatr Adolesc Med 162:929-935.
42. McKean A, Monasterio E (2012) Off-label use of atypical antipsychotics: cause for concern? CNS Drugs 26:383-390.
43. Mitchell M, Riesenberg R, Bari MA, Marquez E, Kurtz D, Falk D, Hardy T, Taylor CC, Mitchell CP, Cavazzoni P (2006) A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects. Clin Ther 28:881-892. (Pubitemid 44062696)
44. Monzillo LU, Hamdy O (2003) Evaluation of insulin sensitivity in clinical practice and in research settings. Nutr Rev 61:397-412. (Pubitemid 38140057)
45. Muniyappa R, Lee S, Chen H, Quon MJ (2008) Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 294:E15-26.
46. Newcomer JW (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19(Suppl. 1):1-93. (Pubitemid 40677047)
47. O'Gorman DJ, Karlsson HK, McQuaid S, Yousif O, Rahman Y, Gasparro D, Glund S, Chibalin AV, Zierath JR, Nolan JJ (2006) Exercise training increases insulin-stimulated glucose disposal and GLUT4 (SLC2A4) protein content in patients with type 2 diabetes. Diabetologia 49:2983-2992. (Pubitemid 44730302)
48. Park S, Hong SM, Lee JE, Sung SR (2007) Chlorpromazine exacerbates hepatic insulin sensitivity via attenuating insulin and leptin signaling pathway, while exercise partially reverses the adverse effects. Life Sci 80:2428-2435. (Pubitemid 46839073)
49. Park T, Usher K, Foster K (2011) Description of a healthy lifestyle intervention for people with serious mental illness taking second-generation antipsychotics. Int J Ment Health Nurs 20:428-437.
50. Patil BM, Kulkarni NM, Unger BS (2006) Elevation of systolic blood pressure in an animal model of olanzapine induced weight gain. Eur J Pharmacol 551:112-115. (Pubitemid 44649297)
51. Pouzet B, Mow T, Kreilgaard M, Velschow S (2003) Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacol Biochem Behav 75:133-140. (Pubitemid 36577588)
52. Procyshyn RM, Honer WG, Wu TK, Ko RW, McIsaac SA, Young AH, Johnson JL, Barr AM (2010) Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J Clin Psychiatry 71:566-573.
53. Reynolds MA, Aichelmann-Reidy ME, Kassolis JD, Prasad HS, Rohrer MD (2007) Calcium sulfate-carboxymethylcellulose bone graft binder: histologic and morphometric evaluation in a critical size defect. J Biomed Mater Res B Appl Biomater 83:451-458. (Pubitemid 350005016)
54. Rosenheck RA, Davis S, Covell N, Essock S, Swartz M, Stroup S, McEvoy J, Lieberman J (2009) Does switching to a new antipsychotic improve outcomes? Data from the CATIE trial. Schizophr Res 107:22-29.
55. Sacher J, Mossaheb N, Spindelegger C, Klein N, Geiss-Granadia T, Sauermann R, Lackner E, Joukhadar C, Muller M, Kasper S (2008) Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers. Neuropsychopharmacology 33:1633-1641. (Pubitemid 351684708)
56. Short KR, Pratt LV, Teague AM (2012) The acute and residual effect of a single exercise session on meal glucose tolerance in sedentary young adults. J Nutr Metab 2012:278678.
57. Skrede S, Ferno J, Vazquez MJ, Fjaer S, Pavlin T, Lunder N, Vidal-Puig A, Dieguez C, Berge RK, Lopez M, Steen VM (2012) Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats. Int J Neuropsychopharmacol 15:163-179.
58. Smith GC, Chaussade C, Vickers M, Jensen J, Shepherd PR (2008) Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat. Diabetologia 51:2309-2317.
59. Smith GC, Vickers MH, Shepherd PR (2011) Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat. Arch Physiol Biochem 117(4):241-249.
60. Suwa M, Yamamoto KI, Nakano H, Sasaki H, Radak Z, Kumagai S (2010) Brain-derived neurotrophic factor treatment increases the skeletal muscle glucose transporter 4 protein expression in mice. Physiol Res 59:619-623.
61. van Dijk JW, Tummers K, Stehouwer CD, Hartgens F, van Loon LJ (2012) Exercise therapy in type 2 diabetes: is daily exercise required to optimize glycemic control? Diabetes Care 35:948-954.
62. Victoriano M, Hermier D, Even PC, Fromentin G, Huneau JF, Tome D, de Beaurepaire R (2009) Early perturbation in feeding behaviour and energy homeostasy in olanzapine-treated rats. Psychopharmacology (Berl) 206:167-176.
63. Vidarsdottir S, de Leeuw van Weenen JE, Frolich M, Roelfsema F, Romijn JA, Pijl H (2010) Effects of olanzapine and haloperidol on the metabolic status of healthy men. J Clin Endocrinol Metab 95:118-125.
64. Vistisen K, Loft S, Poulsen HE (1991) Cytochrome P450 IA2 activity in man measured by caffeine metabolism: effect of smoking, broccoli and exercise. Adv Exp Med Biol 283:407-411.
65. Wang Y, Simar D, Fiatarone Singh MA (2009) Adaptations to exercise training within skeletal muscle in adults with type 2 diabetes or impaired glucose tolerance: a systematic review. Diabetes Metab Res Rev 25:13-40.
66. Weston-Green K, Huang XF, Deng C (2010) Sensitivity of the female rat to olanzapine-induced weight gain-far from the clinic? Schizophr Res 116:299-300.
67. Weston-Green K, Huang XF, Deng C (2011) Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats. Behav Brain Res 217:337-346.
68. Zhang G, Terry AV Jr., Bartlett MG (2007) Simultaneous determination of five antipsychotic drugs in rat plasma by high performance liquid chromatography with ultraviolet detection. J Chromatogr B, Analyt Technol Biomed Life Sci 856:20-28. (Pubitemid 47302895)